FIELD: pharmaceutics.
SUBSTANCE: invention relates to a compound of formula I or to its pharmaceutically acceptable salt. In formula I, Y is a five-element heteroaryl containing 2-3 heteroatoms, each of which is independently selected from a group consisting of N; Z is a phenyl, optionally substituted with 1 or 2 halogens; each R1a and R1b is independently selected from a group consisting of H, C1-C6 alkyl. The invention also relates to the compound of formula II, to the compound of formula III, and to individual compounds.
EFFECT: technical result is that new compounds are obtained as a stimulator of the cystic fibrosis transmembrane conductance regulator (CFTR).
21 cl, 99 ex
Title | Year | Author | Number |
---|---|---|---|
PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | 2017 |
|
RU2757457C2 |
PYRROLTRIAZINE KINASE INHIBITORS | 2000 |
|
RU2331640C2 |
OCTAHYDRO FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | 2014 |
|
RU2674983C1 |
HETEROCYCLIC ARYL SULPHONES, SUITABLE FOR TREATING DISORDERS RESPONSIVE TO 5HT RECEPTOR MODULATION | 2007 |
|
RU2451012C2 |
SUBSTITUTED PYRROLES ACTIVE AS KINASES INHIBITORS | 2013 |
|
RU2666538C2 |
TRIAZOLO-PYRIMIDINE COMPOUNDS AND THEIR USE | 2019 |
|
RU2802866C2 |
BICYCLIC LACTAMS AND METHODS FOR USE THEREOF | 2016 |
|
RU2716136C2 |
MONOACYLGLYCEROL LIPASE MODULATORS | 2019 |
|
RU2797323C2 |
AZADECALINS CONDENSED WITH HETEROARYLKETONES - GLUCOCORTICOID RECEPTOR MODULATORS | 2013 |
|
RU2639867C2 |
AMINOPYRAZINE COMPOUNDS WITH THE A2A ANTAGONIST PROPERTIES | 2015 |
|
RU2727805C2 |
Authors
Dates
2021-08-11—Published
2017-12-14—Filed